Kraig Biocraft Laboratories, Inc. Announces Patent Filing On Human Diagnostics Technology

LANSING, Mich., April 10, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories,
Inc. (OTCBB:KBLB) announced today that a provisional patent application
describing a platform for antigen presentation and antibody test kits has been
filed listing Dr. Malcolm Fraser, a member of Kraig's Scientific Advisory Board,
as the named inventor.

The patent application was filed earlier this year by the University of Notre
Dame, where Dr. Fraser heads the University's Laboratory of Molecular Virology.

"The invention describes engineered polymers which incorporate diagnostic
antigens," explained Dr. Malcolm Fraser. "The genetically fused polymers can
potentially be fashioned into a number of different diagnostic test platforms
including serum (blood), salivary, and urine based diagnostics. One of the
advantages of a polymer based diagnostic platform is its ability to incorporate
multiple antigens into a final product simply by weaving the polymers," Fraser
continued. "The result would be a diagnostic tool which could simultaneously
screen for several diseases or for other important parameters."

This is the second patent application of 2008 which was made pursuant to Kraig's
sponsored research program at the University of Notre Dame and which is subject
to Kraig's intellectual property agreement with the University. That agreement
provides for exclusive licensing rights for Kraig sponsored research. It is the
first such patent application made pursuant to that program relating to human
health.

"This ground breaking technology advances Kraig into the growing field of human
and animal diagnostics," said company CEO Kim Thompson. "The tremendous
potential of genetically fused polymers for diagnostics can not be ignored,"
continued Thompson. "Our announcement is a big step toward fulfilling the
promise of genetically engineered fibers for diagnostics and human health."

For more information on Kraig Biocraft Laboratories please visit the Company's
web site: www.KraigLabs.com

The Kraig Biocraft Laboratories, Inc. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=4817

Statements in this press release about the company's future and expectations
other than historical facts are "forward-looking statements." These statements
are made on the basis of management's current views and assumptions. As a
result, there can be no assurance that management's expectations will
necessarily come to pass. These forward-looking statements generally can be
identified by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "forecasts," "estimates", "develops", "researching'" "research,"
"goal," "potential," "could" or other words or phrases of similar import.
Similarly, statements in this release that describe the Company's business
strategy, outlook, objectives, plans, intentions or goals should all be
considered forward-looking statements. All such forward-looking statements are
subject to certain risks and uncertainties that could cause actual results to
differ materially from those in forward-looking statements. Management cautions
that its ability to further its research, and create commercially-viable
products may be affected by the competitive environment, the Company's financial
condition and its ability to raise sufficient capital to meet the financial
obligations of its business plan and to fund its continuing operations.

-0-
CONTACT: Kraig Biocraft Laboratories, Inc.
Kim Thompson, CEO
(517) 336-0807
info@KraigLabs.com